{"id":"W4399012115","doi":"10.1038/s41591-024-03015-5","title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Medical Research Council; Eli Lilly Japan; Mitsubishi Tanabe Pharma Corporation; Relypsa; Teijin Pharma; Shionogi; Novo Nordisk; Bayer HealthCare; Intercept Pharmaceuticals; National Institutes of Health; Mylan; Astellas Pharma; FibroGen; MannKind Corporation; CSL Behring; National Institute for Health and Care Research; ReCor Medical; Intarcia Therapeutics; Boehringer Ingelheim Japan; Public Health England; McMaster University; Esperion Therapeutics; Alnylam Pharmaceuticals; British Heart Foundation; Brigham and Women's Hospital; Novartis Pharma; European Commission; Kowa Company; Sanofi; GlaxoSmithKline; Novo Nordisk Pharma; Amgen; Pfizer; Bayer Yakuhin; Celgene; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Akebia Therapeutics; Bristol-Myers Squibb","keywords":"Semaglutide; Medicine; Disease; Obesity; Term (time); Internal medicine; Kidney disease; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology; Liraglutide","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008396985,0.000154366,0.0005186764,0.000268171,0.00001386983,0.000007527338,0.00008402402,0.00009196452,0.00003584336],"category_scores_gemma":[0.0004534189,0.00007949073,0.0001371846,0.0004413774,0.00008627639,0.00003331983,0.00003296176,0.0004021211,0.000002219445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004657167,"about_ca_system_score_gemma":0.00006458229,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008270458,"about_ca_topic_score_gemma":0.00003725929,"domain_scores_codex":[0.9987481,0.00008336072,0.0002335742,0.0002687229,0.0004853365,0.0001809065],"domain_scores_gemma":[0.9993501,0.0001456982,0.00002029749,0.0003472432,0.0000210459,0.0001155655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001791626,0.0003981787,0.9754831,0.001185416,0.001105089,0.001770253,0.0007415381,0.000002664112,0.00003845473,0.0006569402,0.004123999,0.01270276],"study_design_scores_gemma":[0.02453739,0.0003903744,0.9675826,0.0009715216,0.001486338,0.0000047415,0.00005051128,0.00006966558,0.00003647813,0.0001661248,0.004622543,0.00008171049],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.949964,0.03951713,0.000006138201,0.007969242,0.000381807,0.001154494,0.000005136106,0.00002776405,0.0009742279],"genre_scores_gemma":[0.9974816,0.000572599,0.00001722658,0.001188472,0.0002328314,0.00004151687,0.00004723796,0.00001161801,0.0004068473],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04751759,"threshold_uncertainty_score":0.3241538,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009524700846208177,"score_gpt":0.2818829617407348,"score_spread":0.2723582608945266,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}